Germline?Targeting HIV Vaccine Generates Broadly Neutralizing Antibodies in Primates

For years, HIV has resisted traditional vaccine strategies. The virus’s staggering antigenic diversity, rapid mutation rate, and glycan?shielded envelope have made it extraordinarily difficult for the immune system to generate antibodies capable of recognizing HIV’s vulnerable sites. Yet a small number of people living with HIV do develop broadly neutralizing antibodies (bnAbs)—rare antibodies that can target conserved regions of the virus despite its shape?shifting defenses. These bnAbs have long been viewed as templates for next?generation vaccine design, but reliably eliciting them through vaccination has remained out of reach.

A team led by scientists at La Jolla Institute for Immunology (LJI) and Scripps Research now reports a potential breakthrough. In a study published in Nature, the researchers demonstrated that a germline?targeting HIV vaccine can elicit bnAbs in outbred nonhuman primates. The study is titled, “Vaccination elicits HIV broadly neutralizing antibodies in primates.”